Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trial
Argenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition.
The result marks an unusual setback for the company, which has recently reported a string of positive outcomes in other autoimmune indications and has been building a reputation as a leading biotech.
Following the news, Argenx shares fell about 13% in early trading, reflecting investor concern over the failed late‑stage readout and its impact on the drug's future development prospects.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease”
read at STAT ↗
comments(0)
5-min edit window · permanent after that